Aitia Partners with Gustave Roussy for Cancer Research Advancements
Deep Knowledge of Disease Causality Can Lead to Transformative New Treatment Approaches that Significantly Improve Patient Outcomes
In an exciting collaboration, Aitia, known for its innovative approach to computational biology, has collaborated with Gustave Roussy, a leading European cancer research institution. Together, they aim to harness the vast cancer patient data from Gustave Roussy to create advanced digital models, referred to as 'Gemini Digital Twins.' These computer-based models will unveil the complex biological foundations of diverse cancers, paving the way for new therapeutic developments and clinical advancements.
Cancer encompasses over 200 distinct diseases, primarily characterized by uncontrolled cell growth, and remains a leading cause of mortality around the globe, rivaled only by cardiovascular diseases. Recent trends indicate a troubling increase in cancer diagnoses among younger adults, and overall case rates have returned to pre-pandemic levels. Despite some advancements, many cancers, such as those affecting the brain, pancreas, and ovaries, persist with inadequate treatment options. The partnership between Aitia and Gustave Roussy aims to break this pattern, addressing critical medical needs prevalent in many cancer types.
Colin Hill, CEO and co-founder of Aitia, emphasizes the significance of decoding the intricate biological changes that provoke cancer. He believes that with insights derived from Gustave Roussy's extensive collection of de-identified multiomic and patient outcome data, Aitia can illuminate pathways to developing the next generation of effective treatments. The organization envisions a scenario whereby discovering these causal underpinnings leads to legitimate breakthroughs in drug discovery and clinical applications.
Prof. Fabrice Barlesi, CEO of Gustave Roussy, expressed enthusiasm about this partnership, noting that both institutions share a mission to apply new findings in cancer biology toward enhanced treatment approaches. Aitia's prowess in modeling complex biological interactions provides a vital advantage as they tackle the challenges posed by various cancers, instilling hope in patients and families around the world.
About Aitia
Aitia strives to create a well-rounded understanding of the complex molecular systems that underlie human health and disease. The company collaborates closely with others to leverage this understanding into the delivery of a new generation of effective therapeutics. Its robust causal AI engine, known as REFS, utilizes cutting-edge computational power to analyze extensive multiomic and patient data, resulting in comprehensive and unbiased in silico models, or 'Gemini Digital Twins.' These models aid in identifying rational drug targets, patient populations suitable for clinical trials, and optimal drug combinations across various diseases.
To date, Aitia has generated valuable insights that accelerate research and development in pharmaceuticals, facilitating breakthroughs in conditions such as Alzheimer's Disease, Parkinson's Disease, multiple myeloma, and several types of cancer. The company has forged collaborations with numerous pharmaceutical industries, eminent academic research centers, medical societies, leading multiomic data firms, and patient advocacy groups, enhancing its influence and reach in the healthcare landscape.
About Gustave Roussy
As a premier cancer center in France and Europe, Gustave Roussy holds an esteemed position globally, devoted entirely to patient care for those battling cancer. It is a founding member of the Paris Saclay Cancer Cluster, recognized for its critical contributions to diagnostic and therapeutic advancements. Treating close to 50,000 patients annually, Gustave Roussy combines rigorous research with personalized patient care, addressing the needs of individuals of all ages while specializing in rare and complex cancer cases. Their holistic approach ensures patients receive not just medical care but also respect for their psychological and social well-being.
In addition to outstanding treatment quality, Gustave Roussy engages approximately 40% of its patients in clinical studies, fostering an environment where innovative research and patient therapy coalesce.
Aitia Media Contact:
Fintan R. Steele, PhD
+1 617-816-9834
Gustave Roussy Media Contact:
Claire Parisel, Public Relations
+33-617660026
Frequently Asked Questions
What is the focus of the collaboration between Aitia and Gustave Roussy?
The collaboration aims to analyze cancer patient data to create digital models that reveal the biological causes of cancer, improving treatment options.
How will 'Gemini Digital Twins' help in cancer research?
These models will provide insights into the underlying biological mechanisms of cancer, facilitating the development of effective treatments.
What types of cancers are being targeted by this partnership?
The partnership focuses on various cancers, especially those with significant unmet medical needs, such as brain, pancreatic, and ovarian cancers.
Who leads Aitia and Gustave Roussy?
Colin Hill is the CEO of Aitia, while Prof. Fabrice Barlesi serves as the CEO of Gustave Roussy.
How significant is Gustave Roussy in the cancer research landscape?
Gustave Roussy is ranked as a leading cancer center in Europe and is recognized for its contributions to diagnostics, patient care, and research, treating nearly 50,000 patients each year.
